An Eph family receptor found abundantly in tissues of epithelial origin. It is expressed in a diverse array of tissues during embryonic development, suggesting that it may play a role in embryogenesis. In adult tissues high levels of the receptor are expressed in the LUNG; SKIN; SMALL INTESTINE and OVARY.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Established cell cultures that have the potential to propagate indefinitely.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT).
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Antibodies produced by a single clone of cells.
Measurement of blood flow based on induction at one point of the circulation of a known change in the intravascular heat content of flowing blood and detection of the resultant change in temperature at a point downstream.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Sites on an antigen that interact with specific antibodies.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)
Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.
A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Theory and development of COMPUTER SYSTEMS which perform tasks that normally require human intelligence. Such tasks may include speech recognition, LEARNING; VISUAL PERCEPTION; MATHEMATICAL COMPUTING; reasoning, PROBLEM SOLVING, DECISION-MAKING, and translation of language.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
The etiologic agent of PLAGUE in man, rats, ground squirrels, and other rodents.
An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
A species of the genus YERSINIA, isolated from both man and animal. It is a frequent cause of bacterial gastroenteritis in children.
Exclusive legal rights or privileges applied to inventions, plants, etc.
Infections with bacteria of the genus YERSINIA.
Substances that are recognized by the immune system and induce an immune reaction.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A signal transducing tumor necrosis factor receptor associated factor that is involved in TNF RECEPTOR feedback regulation. It is similar in structure and appears to work in conjunction with TNF RECEPTOR-ASSOCIATED FACTOR 1 to inhibit APOPTOSIS.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
The specialty or practice of nursing in the care of patients in the recovery room following surgery and/or anesthesia.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
A flavoprotein that functions as a powerful antioxidant in the MITOCHONDRIA and promotes APOPTOSIS when released from the mitochondria. In mammalian cells AIF is released in response to pro-apoptotic protein members of the bcl-2 protein family. It translocates to the CELL NUCLEUS and binds DNA to stimulate CASPASE-independent CHROMATIN condensation.
Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.
A polynucleotide formed from the ADP-RIBOSE moiety of nicotinamide-adenine dinucleotide (NAD) by POLY(ADP-RIBOSE) POLYMERASES.
A family of wingless, blood-sucking insects of the suborder HETEROPTERA, including the bedbugs and related forms. Cimex (BEDBUGS), Heamatosiphon, and Oeciacus are medically important genera. (From Dorland, 28th ed)
The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability.
A receptor-regulated smad protein that undergoes PHOSPHORYLATION by ACTIVIN RECEPTORS, TYPE I. Activated Smad3 can bind directly to DNA, and it regulates TRANSFORMING GROWTH FACTOR BETA and ACTIVIN signaling.
A signal transducing adaptor protein and tumor suppressor protein. It forms a complex with activated RECEPTOR-REGULATED SMAD PROTEINS. The complex then translocates to the CELL NUCLEUS and regulates GENETIC TRANSCRIPTION of target GENES.
A family of transcription factors characterized by the presence of highly conserved calcineurin- and DNA-binding domains. NFAT proteins are activated in the CYTOPLASM by the calcium-dependent phosphatase CALCINEURIN. They transduce calcium signals to the nucleus where they can interact with TRANSCRIPTION FACTOR AP-1 or NF-KAPPA B and initiate GENETIC TRANSCRIPTION of GENES involved in CELL DIFFERENTIATION and development. NFAT proteins stimulate T-CELL activation through the induction of IMMEDIATE-EARLY GENES such as INTERLEUKIN-2.
An inhibitory smad protein that associates with TRANSFORMING GROWTH FACTOR BETA RECEPTORS and BONE MORPHOGENETIC PROTEIN RECEPTORS. It negatively regulates SIGNAL TRANSDUCTION PATHWAYS by inhibiting PHOSPHORYLATION of RECEPTOR-REGULATED SMAD PROTEINS.
A receptor-regulated smad protein that undergoes PHOSPHORYLATION by BONE MORPHOGENETIC PROTEIN RECEPTORS. It regulates BONE MORPHOGENETIC PROTEIN signaling and plays an essential role in EMBRYONIC DEVELOPMENT.
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.

Identification of CD137 as a potent monocyte survival factor. (1/282)

CD137 (ILA/4-1BB), a member of the tumor necrosis factor (TNF) receptor family, promotes adherence and prolongs survival of human peripheral monocytes. It induces a strong expression of macrophage colony-stimulating factor (M-CSF), an essential monocyte survival factor. Monocyte survival induced by CD137 is primarily mediated by M-CSF and to a lesser extent by granulocyte-macrophage colony-stimulating factor and IL-3. Survival and induction of M-CSF are mediated via reverse signaling through a CD137 ligand expressed constitutively by peripheral monocytes.  (+info)

CD137-induced apoptosis is independent of CD95. (2/282)

CD95 (APO-1/Fas) and CD137 (ILA/4-1BB) are members of the tumour necrosis factor receptor family, and both are involved in induction of apoptosis in lymphocytes. Contrary to the case of CD95, apoptosis by CD137 is caused by cross-linking of the respective ligand rather than the receptor. Nothing is known so far about the mechanism of CD137-induced cell death. Here, we show that immobilized CD137 protein induces expression of CD95 in resting primary T and B lymphocytes. However, induction of apoptosis by CD137 is independent of CD95, because: (1) antagonistic anti-CD95 antibody fragments do not block CD137-induced apoptosis; and (2) CD137, but not anti-CD95, can induce apoptosis in resting lymphocytes.  (+info)

Role of the stress kinase pathway in signaling via the T cell costimulatory receptor 4-1BB. (3/282)

4-1BB is a member of the TNFR superfamily expressed on activated CD4+ and CD8+ T cells. 4-1BB can costimulate IL-2 production by resting primary T cells independently of CD28 ligation. In this study, we report signaling events following 4-1BB receptor aggregation using an Ak-restricted costimulation-dependent T cell hybridoma, C8.A3. Aggregation of 4-1BB on the surface of C8.A3 cells induces TNFR-associated factor 2 recruitment, which in turn recruits and activates apoptosis signal-regulating kinase-1, leading to downstream activation of c-Jun N-terminal/stress-activated protein kinases (JNK/SAPK). 4-1BB ligation also enhances anti-CD3-induced JNK/SAPK activation in primary T cells. Overexpression of a catalytically inactive form of apoptosis signal-regulating kinase-1 in C8.A3 T cells interferes with activation of the SAPK cascade and with IL-2 secretion, consistent with a critical role for JNK/SAPK activation in 4-1BB-dependent IL-2 production. Given the ability of both CD28 and 4-1BB to induce JNK/SAPK activation, we asked whether hyperosmotic shock, another inducer of this cascade, could function to provide a costimulatory signal to T cells. Osmotic shock of resting primary T cells in conjunction with anti-CD3 treatment was found to costimulate IL-2 production by the T cells, consistent with a pivotal role for JNK/SAPK in T cell costimulation.  (+info)

The structural basis for the recognition of diverse receptor sequences by TRAF2. (4/282)

Many members of the tumor necrosis factor receptor (TNFR) superfamily initiate intracellular signaling by recruiting TNFR-associated factors (TRAFs) through their cytoplasmic tails. TRAFs apparently recognize highly diverse receptor sequences. Crystal structures of the TRAF domain of human TRAF2 in complex with peptides from the TNFR family members CD40, CD30, Ox40, 4-1BB, and the EBV oncoprotein LMP1 revealed a conserved binding mode. A major TRAF2-binding consensus sequence, (P/S/A/T)x(Q/E)E, and a minor consensus motif, PxQxxD, can be defined from the structural analysis, which encompass all known TRAF2-binding sequences. The structural information provides a template for the further dissection of receptor binding specificity of TRAF2 and for the understanding of the complexity of TRAF-mediated signal transduction.  (+info)

CD137 induces proliferation and endomitosis in monocytes. (5/282)

Peripheral monocytes are short-lived and are replenished from hematopoietic stem cells whose proliferation is believed to be confined to the bone marrow. Human peripheral monocytes are assumed not to be able to proliferate. In this study we show that CD137 (ILA/4-1BB), a member of the tumor necrosis factor receptor family, induces a widespread and profound proliferation of human peripheral monocytes. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor are essential, but not sufficient for proliferation. Additional soluble autocrine factors induced by CD137 are required. Induction of proliferation is mediated via reverse signaling through a CD137 ligand, expressed constitutively by peripheral monocytes. The ability of CD137 to induce proliferation in human peripheral monocytes is not shared by any other known molecule.  (+info)

Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. (6/282)

The 4-1BB receptor (CDw137), a member of the tumor necrosis factor receptor superfamily, has been shown to costimulate the activation of T cells. Here we show that anti-mouse 4-1BB monoclonal antibodies (mAbs) inhibit thymus-dependent antibody production by B cells. Injection of anti-4-1BB mAbs into mice being immunized with cellular or soluble protein antigens induced long-term anergy of antigen-specific T cells. The immune response to the type II T cell-independent antigen trinintrophenol-conjugated Ficoll, however, was not suppressed. Inhibition of humoral immunity occurred only when anti-4-1BB mAb was given within 1 wk after immunization. Anti-4-1BB inhibition was observed in mice lacking functional CD8(+) T cells, indicating that CD8(+) T cells were not required for the induction of anergy. Analysis of the requirements for the anti-4-1BB-mediated inhibition of humoral immunity revealed that suppression could not be adoptively transferred with T cells from anti-4-1BB-treated mice. Transfer of BALB/c splenic T cells from sheep red blood cell (SRBC)-immunized and anti-4-1BB-treated mice together with normal BALB/c B cells into C.B-17 severe combined immunodeficient mice failed to generate an anti-SRBC response. However, B cells from the SRBC-immunized, anti-4-1BB-treated BALB/c mice, together with normal naive T cells, exhibited a normal humoral immune response against SRBC after transfer, demonstrating that SRBC-specific B cells were left unaffected by anti-4-1BB mAbs.  (+info)

CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. (7/282)

Human CD137 is a member of the tumor necrosis factor (TNF) receptor family and the homologue of murine 4-1BB. Recent studies have demonstrated that CD137 promotes accessory T cell activation, and regulates proliferation and survival of T lymphocytes. This study reports on the expression and function of CD137 in peripheral blood monocytes. While monocytes showed constitutive expression in 10 out of 18 healthy donors, CD137 was not expressed on resting T or B lymphocytes. Immobilized antibodies to CD137 markedly induced the production of IL-8 and TNF-alpha protein and mRNA, and led to inhibition of IL-10 expression by primary monocytes. Furthermore, cross-linking of CD137 on monocytes resulted in an increase of B lymphocyte apoptosis mediated by direct cell-cell contact of both cell populations. In conclusion, this study identified CD137 as a new receptor involved in monocyte activation by inducing a characteristic cytokine release profile. In addition, CD137 may play a role in monocyte-dependent control of B lymphocyte survival.  (+info)

4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. (8/282)

Peptide vaccination induces T cell activation and cytotoxic T cell development. In an effort to understand what factors can improve immune responses to peptide vaccination, the role of 4-1BB (CD137) costimulation was examined, since 4-1BB has been shown to promote T cell responses in other systems. 4-1BBL-deficient (-/-) and wild-type (+/+) mice were immunized with a lipidated lymphocytic choriomeningitis virus (LCMV) peptide NP396-404. Analysis of peptide-specific responses early after immunization by CTL assay, intracellular IFN-gamma staining, and IFN-gamma enzyme-linked immunospot assay (ELISPOT) indicated that CD8 T cell responses were reduced 3- to 10-fold in the absence of 4-1BB costimulation. Moreover, when agonistic anti-4-1BB Ab was given, CD8 T cell responses in 4-1BBL-/- mice were augmented to levels similar to those in 4-1BBL+/+ mice. Two months after immunization, 4-1BBL+/+ mice still had epitope-specific cells and were protected against viral challenge, demonstrating that peptide vaccination can induce long-term protection. In fact, 70% of CD8 T cells were specific for the immunizing peptide after viral challenge, demonstrating that strong, epitope-specific CD8 T cell responses are generated after peptide vaccination. In contrast, peptide-immunized 4-1BBL-/- mice had fewer epitope-specific cells and were impaired in their ability to resolve the infection. These results show that immunization with a single LCMV peptide provides long term protection against LCMV infection and point to costimulatory molecules such as 4-1BB as important components for generating protective immunity after vaccination.  (+info)

Purpose: Cultured tumor fragments from melanoma metastases have been used as a source of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy. The expansion of tumor-reactive CD8+ T cells with IL-2 in these early cultures is critical in generating clinically active TIL infusion products, with a population of activated 4-1BB CD8+ T cells recently found to constitute the majority of tumor-specific T cells. Experimental Design:We used an agonistic anti-4-1BB antibody added during the initial tumor fragment cultures to provide in situ 4-1BB co-stimulation. Results: Addition of an agonistic anti-4-1BB antibody could activate 4-1BB signaling within early cultured tumor fragments and accelerated the rate of memory CD8+ TIL outgrowth that were highly enriched for melanoma antigen specificity. This was associated with NFkappaB activation and the induction of T-cell survival and memory genes, as well as enhanced IL-2 responsiveness, in the CD8+ T cells in the fragments and emerging from the ...
The LOB12.3 monoclonal antibody reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. 4-1BB is a 39 kDa transmembrane protein expressed by T lymphocytes, NK cells, dendritic cells, granulocytes, and mast cells. Upon binding its ligand 4-1BBL, 4-1BB provides costimulatory signals to both CD4 and CD8 T cells through the activation of NF- κB, c-Jun and p38 downstream pathways. The importance of the 4-1BB pathway has been underscored in a number of diseases, including cancer. Agonistic anti-4-1BB antibodies have been reported to induce T cell mediated antitumor immunity. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growth |em|in vivo|/em| when administered in combination with immune checkpoint inhibitors.
Sires With Kappa Casein BB/AB & Fleckvieh/Milking-Simmentals & Cow - Besamungsunternehemen Rind Schwein Embryotransfer Managementberatung
Sires With Kappa Casein BB/AB & Fleckvieh/Milking-Simmentals & Cow - Besamungsunternehemen Rind Schwein Embryotransfer Managementberatung
I noticed some play in the BB on my Trek Cronus CX. Removed the cranks on NDS bearing but I cant remove the DS bearing. Even with the appropriate Park Tool there is not enough room behind the bearing for the bushing to sit and hit against because of a plastic sleeve which runs between the two bearings. I tried to slide the sleeve to the side but it wont budge ...
ilaç hammaddeleri, Şunları yapabilirsiniz satın al iyi kalite ilaç hammaddeleri , Biz ilaç hammaddeleri Distribütör & ilaç hammaddeleri Üretici Çinden Pazar.
la barkod listesi i erisinde 9961 ila bulunmakta olup 161. sayfa i erisindeki 50 ila g r nt lenmektedir. Sorgulama formunu kullanarak barkod numaras ile ila aramas yapabilirsiniz.
Gjenerata e fundit e barnave, të zhvilluara duke përdorur teknologji moderne farmaceutike, lehtësojnë vuajtjet njerëzore, zvogëlojnë rrezikun e
引用Abcams Anti-53BP1抗体(ab21083)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
Treatment of advanced, poorly immunogenic tumors in animal models, considered the closest simulation available thus far for conditions observed in cancer patients, remains a major challenge for cancer immunotherapy. We reported previously that established tumors in mice receiving an agonistic mAb to the T cell costimulatory molecule 4-1BB (CD137) regress due to enhanced tumor antigen-specific cytotoxic T lymphocyte responses. In this study, we demonstrate that several poorly immunogenic tumors, including C3 tumor, TC-1 lung carcinoma, and B16-F10 melanoma, once established as solid tumors or metastases, are refractory to treatment by anti-4-1BB mAb. We provide evidence that immunological ignorance, rather than anergy or deletion, of tumor antigen-specific CTLs during the progressive growth of tumors prevents costimulation by anti-4-1BB mAb. Breaking CTL ignorance by immunization with a tumor antigen-derived peptide, although insufficient to stimulate a curative CTL response, is necessary for ...
Description: 4-1BB Receptor, a member of the TNF superfamily of receptors, is mainly expressed on the surface of a variety of T cells, but also found in B cells, monocytes, and various transformed cell lines. 4-1BB Receptor binds to 4-1BBL to provide a co-stimulatory signal for T lymphocytes. Signaling by 4-1BB Receptor has been implicated in the antigen-presentation process and generation of cytotoxic T cells. The human 4-1BB Receptor gene codes for a 255 amino acid type I transmembrane protein containing a 17 amino acid N-terminal signal sequence, a 169 amino acid extracellular domain, a 27 amino acid transmembrane domain and a 42 amino acid cytoplasmic domain. Recombinant human soluble 4-1BB Receptor is a 167 amino acid polypeptide (17.7 kDa), which contains the cysteine rich TNFR-like extracellular domain of 4-1BB Receptor ...
Description: 4-1BB Receptor, a member of the TNF superfamily of receptors, is mainly expressed on the surface of a variety of T cells, but also found in B cells, monocytes, and various transformed cell lines. 4-1BB Receptor binds to 4-1BBL to provide a co-stimulatory signal for T lymphocytes. Signaling by 4-1BB Receptor has been implicated in the antigen-presentation process and generation of cytotoxic T cells. The human 4-1BB Receptor gene codes for a 255 amino acid type I transmembrane protein containing a 17 amino acid N-terminal signal sequence, a 169 amino acid extracellular domain, a 27 amino acid transmembrane domain and a 42 amino acid cytoplasmic domain. Recombinant human soluble 4-1BB Receptor is a 167 amino acid polypeptide (17.7 kDa), which contains the cysteine rich TNFR-like extracellular domain of 4-1BB Receptor ...
4-1BBL, a member of the TNF superfamily, is expressed in B cells, dendritic cells, activated T cells and macrophages. 4-1BBL binds to its receptor
A membrane bound member of the TNF superfamily that is expressed on activated B-LYMPHOCYTES; MACROPHAGES; and DENDRITIC CELLS. The ligand is specific for the 4-1BB RECEPTOR and may play a role in inducing the proliferation of activated peripheral blood T-LYMPHOCYTES ...
Example of Table 22.3. Here is the Scalogram for Example 5, a computer-adaptive, multiple-choice test. The original responses are shown.. GUTTMAN SCALOGRAM OF ORIGINAL RESPONSES:. STUDENT ,TOPIC. , 11 3 11 1 3212232212132425654421434145625 36555366356465464633654. ,640215038189677748390992315641640517264579268221076889430372139553458. ,---------------------------------------------------------------------. 3 + d b c db d c b cd S STA. 6 + c b c d d c cd S CHU. 27 + c c c c cbb a dd c b dd S ERI. 4 + c b a d cb c dd d b d dc S CHE. 9 + d c a a cbc c ba b dca c db dc bbdbb c S MEL. 25 + c b d c bc a a d a c dba d cbccbd c S DAN. 24 + a d ac b c d c b a a AP SAR. 12 + c b c c b b b b a cb cc c A ALL. 28 + c c a bcc b c acc d b bc b c bdcb d IH GRE. 21 + b c b a c b a bc bb ab a db bbd cc b b AP MIL. 11 + a d c b cc cbad d ca c d ca ba b ac bac bc d c cc S CHR. 17 + d d c c acac cac b c a a b c c bc b ac ac IH FRA. 7 + d c d ccaaac d bcd ca b cb c b a a a a ab b bb ac IH JAN. 1 + c c ab ca dc b a a c ...
Looking for Forever Young BBL™ Photorejuvenation in Modesto, CA? Call 209-890-4470 to schedule your private consultation at Skinfinite Solutions.
View mouse Tnfrsf18 Chr4:156026164-156028895 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
View mouse Tnfrsf13b Chr11:61126755-61149372 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
The KOMP Repository is located at the University of California Davis and Childrens Hospital Oakland Research Institute. Question? Comments? For Mice, Cells, and germplasm please contact us at [email protected], US 1-888-KOMP-MICE or International +1-530-752-KOMP, or for vectors [email protected] or +1-510-450-7917 ...
The KOMP Repository Collection is located at the MMRRC at the University of California, Davis and Childrens Hospital Oakland Research Institute. Question? Comments? For Mice, Cells, and germplasm please contact us at [email protected], US 1-888-KOMP-MICE or International +1-530-752-KOMP, or for vectors [email protected] or +1-510-450-7917 ...
These reference sequences exist independently of genome builds. Explain. These reference sequences are curated independently of the genome annotation cycle, so their versions may not match the RefSeq versions in the current genome build. Identify version mismatches by comparing the version of the RefSeq in this section to the one reported in Genomic regions, transcripts, and products above. ...
Dose-limiting toxicity of cancer drugs is a main hurdle facing the development of effective treatments for cancer. Immunostimulatory drugs are no different. Ipilimumab, a monoclonal antibody that blocks the function of the coinhibitory receptor CTLA-4, is the first U.S. Food and Drug Administration-approved immunostimulatory antibody that has shown clinical benefit in patients with cancer. Nonetheless, ipilimumab treatment is associated with significant dose-dependent toxicities and grade 3 to 4 adverse effects including colitis and hypophysitis (26). Likewise, treatment with an agonistic 4-1BB antibody while showing antitumor efficacy was also associated with grade 3 or higher neutropenia and elevated liver enzymes (27), and severe hepatic toxicity at higher doses that led to the suspension of the clinical trial (27, 28). The potential toxicity of immunostimulatory antibodies was underscored by unexpected severe toxicities seen in healthy volunteers treated with a super agonistic anti-CD28 ...
Supplementary MaterialsSupp Numbers1-S6. memory space cells was T-cell-intrinsic. Therefore, c-IAP E3 activity is required for 4-1BB co-receptor signaling and maintenance of CD8+ T-cell memory space. infection due to very high effector cytokine levels produced during the main effector response [27]. Using these mice, we have EMD534085 analyzed 4-1BB signaling and both the acute and memory space response to LCMV. We find that signaling downstream 4-1BB, and consequently the maintenance of a functional and effective pool of memory space T cells, requires c-IAP E3 activity. Results Impaired 4-1BB-induced signaling in c-IAP2H570A T cells In vitro studies have shown that engagement of 4-1BB on T cells induces the activation of the canonical NF-B pathway inside a c-IAP-dependent manner [18C20, 24]. We analyzed the part of c-IAP E3 activity in this process by taking advantage of mice in which endogenous c-IAP2 has been replaced with an E3-inactive point mutant, c-IAP2H570A, that also functions as ...
根據歐洲醫學期刊指出,淨透明亮膚質是肌膚看起來年輕、健康的關鍵,同時也顯著影響個人吸引力;而擁有光滑勻亮的膚色,也會使人看起來更年輕,魅力也因此提升。每個文化對美的標準有所不同,亞洲女性在乎肌膚暗沉、斑點、膚色不均等肌膚困擾,努力追求更加明亮
Kemoterapi kanser hücrelerinin yok edilmesi için kimyasalların kullanıldığı bir kanser tedavisi şeklidir. Kemoterapi ilaçları tüm vücutta kanser hücrelerine
Tnfrsf1a (untagged) - Mouse tumor necrosis factor receptor superfamily, member 1a (cDNA clone MGC:6117 IMAGE:3585060), (10ug), 10 µg.
HTF Market Intelligence released a new research report of 41 pages on title Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H1 2017 with detailed analysis, forecast and strategies. The study covers key regions and important players such as KAHR medical Ltd, Silence Therapeutics Plc
Tumor necrosis factor receptor superfamily, member 19, also known as TNFRSF19 and TROY is a human gene. The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is highly expressed during embryonic development. It has been shown to interact with TRAF family members, and to activate JNK signaling pathway when overexpressed in cells. This receptor is capable of inducing apoptosis by a caspase-independent mechanism, and it is thought to play an essential role in embryonic development. Alternatively, spliced transcript variants encoding distinct isoforms have been described. GRCh38: Ensembl release 89: ENSG00000127863 - Ensembl, May 2017 GRCm38: Ensembl release 89: ENSMUSG00000060548 - Ensembl, May 2017 Human PubMed Reference:. Mouse PubMed Reference:. Entrez Gene: TNFRSF19 tumor necrosis factor receptor superfamily, member 19. Robertson NG, Khetarpal U, Gutiérrez-Espeleta GA, et al. (1995). Isolation of novel and known genes from a human fetal cochlear ...
Reagents, Tools and Custom Services for molecular biology, specializing in the fields of Nano-Antibody development (nAb), Cellular Reprogramming (iPSC), Genome Editing, Fluorescent Proteins, RNAi, Viral Packaging and Protein expression.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
Get glycol chiller quotes from multiple suppliers based on total brite tanks (no jacketed brite tanks, 1, 2, 3, 4, 5, 6, 7, 8, 9+), winery usage (fermentation vessels, storage / cellar, fermentation and storage, not applicable), total fermenters (no jacketed fermenters, 1, 2, 3, 4, 5, 6, 7, 8, 9+), brewhouse capacity (3 bbl, 3.5 bbl, 5 bbl, 7 bbl, 10 bbl, 15 bbl, 20 bbl, 25 bbl, 30 bbl, 40 bbl, 50 bbl, 60 bbl, 70 bbl, 80 bbl, 90 bbl, 100 bbl), indoor or outdoor (indoors, outdoors, not sure), power supply (triple phase, single phase), fermenter capacity (3 bbl, 3.5 bbl, 5 bbl, 7 bbl, 10 bbl, 15 bbl, 20 bbl, 25 bbl, 30 bbl, 40 bbl, 50 bbl, 60 bbl, 70 bbl, 100 bbl, 200 bbl, 300 bbl, 400 bbl, 500 bbl, 600 bbl, 700 bbl, 800 bbl, 800+ bbl, no jacketed fermenters), application (winery, brewery, pasteurizer, machine cooling, food processing, air conditioning, cidery, distillery, restaurant), wine types (red, white, red and white, not applicable), conditioning tank capacity (3 bbl, 3.5 bbl, 5 bbl, 7 bbl, 10 bbl,
PubMed journal article: Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Download Prime PubMed App to iPhone, iPad, or Android
TNFRSF9 - TNFRSF9 (untagged)-Human tumor necrosis factor receptor superfamily, member 9 (TNFRSF9) available for purchase from OriGene - Your Gene Company.
OPG antibody [13H21] (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)) for WB. Anti-OPG mAb (GTX53424) is tested in Mouse samples. 100% Ab-Assurance.
OPG antibody (Biotin) (tumor necrosis factor receptor superfamily, member 11b) for ELISA, WB. Anti-OPG pAb (GTX18068) is tested in Human samples. 100% Ab-Assurance.
I just installed a Token Tiramic BB on my rain bike. The crankset is an FSA Energy Megaexo. After putting the crank through the Token BB, I needed to pull it to adjust the shims. The drive side bearing is now stuck on the spindle. I installed it, and it spins fine, but Im just wondering how Im going to pull it off when its time to replace it ...
International biotechnology industry analysis, data and networking focused on translation, research, development, regulation, commercialization, partnering and funding.
This Histri was built automatically but not manually verified. As a consequence, the Histri can be incomplete or can contain errors ...
Uradna spletna stran predsednika Republike Slovenije javnosti zagotavlja novice, sporočila in informacije o delu, funkciji in osebnosti predsednika Republike Slovenije.
[65 Pages Report] Check for Discount on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018 report by Global Markets Direct. Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or...
Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Research (2015-2019) and Future Forecast (2020-2025) includes market share, market research report, market trade, market prices, market geography trend and market forecast
Research proven purified goat polyclonal TRAIL R3, DcR 1 or CD263 antibody. DcR1 is attached to the cell surface through glycophospholipid anchor. It has the extracellular TRAIL binding domain but lacks the cytoplasmic domain to induce apoptotic signal. Hence overexpression of DcR1 inhibits the TRAIL induced apoptosis. Designed for immunohistochemistry, western blotting, ELISA and related apllications. IHC image in product description.
The TNFRSF11A gene encodes a member of the TNF receptor family and is therefore involved in regulation of immunen processes. Mutations cause autosomal recessive juvenile Paget disease, osteopetrosis, and dominant familial expansile osteolysis.. ...
TY - JOUR. T1 - 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. AU - Vezys, Vaiva. AU - Penaloza-Macmaster, Pablo. AU - Barber, Daniel L.. AU - Ha, Sang Jun. AU - Konieczny, Bogumila. AU - Freeman, Gordon J.. AU - Mittler, Robert S.. AU - Ahmed, Rafi. PY - 2011/8/15. Y1 - 2011/8/15. N2 - Previous studies have identified the inhibitory role that the programmed death 1 (PD-1) pathway plays during chronic infection. Blockade of this pathway results in rescue of viral-specific CD8 T cells, as well as reduction of viral loads in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). We tested the effect of combining PD ligand 1 (PD-L1) blockade with an agonistic regimen that induces 4-1BB costimulation during chronic LCMV infection. There is a boosting effect in the rescue of LCMV-specific CD8 T cell responses after dual treatment with PD-L1 blockade and 4-1BB agonistic Abs when the amount and timing ...
Glucocorticoid-induced TNFR family related protein (GITR, CD357 or TNFRSF18) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). Like other T cell co-stimulatory TNFR family members, GITR utilizes multiple oligomerization states to regulate the initiation of downstream signaling during T cell activation by antigen presenting cells (APCs). The formation of receptor superclusters, comprised of two or more trimeric molecules, has been defined for multiple TNFRs as a means of regulating downstream signal amplification. For co-stimulatory TNFRs, like GITR, CD137 and OX40, signaling outcomes in T cells are primarily mediated via the NFκB pathway that promotes cell survival and effector cell activities in response to suboptimal T cell receptor (TCR) stimulation. It has been hypothesized that the manipulation of the oligomeric states of co-stimulatory TNFRs using antibodies may have therapeutic utility in enhancing the activity of tumor-reactive T cells, either as single agents or ...
Clone REA738 recognizes the human CD95 antigen, also known as Fas and Apo-1, which is a member of the tumor necrosis factor receptor superfamily (TNFR) and is found on the surface of many normal and neoplastically transformed cells. Its ligand, CD95L (FasL/Apo-1L), is able to induce apoptosis in CD95-expressing cells upon binding. CD95 and CD95L are up-regulated on lymphocytes upon activation and are known to play a key role in the regulation of an inflammatory response: Juxtocrine
CD95, also known as FAS or Apo-1, is a member of the tumor necrosis factor receptor superfamily (TNFR) and is found on the surface of many normal and neoplastically transformed cells. Its ligand, CD95L (FASL/Apo-1L), is able to induce apoptosis in CD95-expressing cells upon binding. CD95 and CD95L are up-regulated on lymphocytes upon activation and are known to play a key role in the regulation of an inflammatory response: Juxtocrine
Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor, is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. Expression of OX40 is dependent on full activation of the T cell; without CD28, expression of OX40 is delayed and of fourfold lower levels ...
PeproTech the producer of high quality recombinant cytokines and growth factors supports life science research, cellular therapy and regenerative medicine.
Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional me …
US High Yield BB Effective Yield historical data, charts, stats and more. US High Yield BB Effective Yield is at 4.32%, compared to 4.31% the previous market day and 4.65% last year. This is lower than the long term average of 7.19%..
I was reading today about the Promises, Page 83-84 from the BB. Those are the famous promises. I was looking though the BB, and found many others. This one stood...
4-1BBL (4-1BB ligand) is found on APCs (antigen presenting cells) and binds to 4-1BB. ... CD137. References[edit]. *^ Lotze, Michael (2001). Dendritic Cells. Boston: Academic Press. ISBN 0-12-455851-8.. ...
CD137: When this molecule, also called 4-1BB, is bound by CD137 ligand, the result is T-cell proliferation. CD137-mediated ... CD27: This molecule supports antigen-specific expansion of naïve T cells and is vital for the generation of T cell memory. CD27 ... The ligand for GITR is mainly expressed on antigen presenting cells. Antibodies to GITR have been shown to promote an anti- ... CD40: This molecule, found on a variety of immune system cells including antigen presenting cells has CD40L, otherwise known as ...
The CD137 presence within the cells maintains the persistence of the engineered T cells. This interaction between engineered T ... cells with CD28 and CD137 are essential for immunotherapy, and show promise for directing T lymphocytes to tumor antigens and ... Additionally, genetically engineered T cells containing CD28 and CD137 can be used in a molecularly targeted therapy response ... established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains". Proceedings of the ...
T cells based on antigen-triggered CD137 expression". Journal of Immunological Methods. 339 (1): 23-37. doi:10.1016/j.jim. ... The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T ... CD137 is expressed by activated T cells of both the CD4+ and CD8+ lineages. Although it is thought to function mainly in co- ... stimulating those cell types to support their activation by antigen presenting cells expressing its ligand (CD137L), CD137 is ...
A number of approaches have been considered to amplify T cell mediated immune responses(e.g. IL-2, CTLA-4, IL-7, CD137), and ... tumor-associated antigens, or whole tumor cells, can induce specific T-cell mediated immune responses. ...
... and CD137 (4‐1BB). The intracellular signaling domain used defines the generation of a CAR T cell. First generation CARs ... Identification of good antigens has been challenging: such antigens must be highly expressed on the majority of cancer cells, ... After an antigen is bound to the external antigen recognition domain, CAR receptors cluster together and transmit an activation ... T cells are genetically engineered to express chimeric antigen receptors specifically directed toward antigens on a patient's ...
This antigen along with other blood group antigens was used to identify the Basque people as a genetically separate group.[49] ... Because the Duffy antigen is uncommon in those of Black African descent, the presence of this antigen has been used to detect ... The Fy4 antigen, originally described on Fy (a-b-) RBCs, is now thought to be a distinct, unrelated antigen and is no longer ... The Duffy antigen is expressed in greater quantities on reticulocytes than on mature erythrocytes.[21] While the Duffy antigen ...
In the TNF family of molecules, the protein 4-1BB (CD137) on the T cell may bind to 4-1BB ligand (4-1BBL) on the APC. The B7 ( ... This is also called "Signal 1" and its main purpose is to guarantee antigen specificity of the T cell activation. However, MHC ... B7 is a type of peripheral membrane protein found on activated antigen-presenting cells (APC) that, when paired with either a ...
Ebert LM, McColl SR (2002). "Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes ... This receptor has been shown to be important for B-lineage maturation and antigen-driven B-cell differentiation, and it may ... dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens". J. Immunol. 167 (11): ...
Antigen CD19 appears only on B cells, which go awry in lymphoma and leukemia. Loss of B cells can be countered with ... potentially including costimulatory domains encoding CD28 or CD137. CARs can provide recognition of cell surface components not ... Cancer-testes antigen MAGE-A3 is not known to be expressed in any normal tissues. However, targeting an HLA-A*0201-restricted ... Cancer-testis antigens are a family of intracellular proteins that are expressed during fetal development, but with little ...
OX40L is the ligand for OX40 (also known as CD134 or TNFRSF4) and is stably expressed on many antigen-presenting cells such as ... December 2002). "Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), ...
Interleukin-3 receptor (takođe poznat kao CD123 antigen) je molekul nađen na ćelijama koje pomažu prenos interleukin-3 signala ...
I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ... results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology. 31 (17): ...
CD97 antigen je protein koji je kod ljudi kodiran CD97 genom.[1][2][3] ... CD137 • CD138 • CD140b • CD141 • CD142 • CD143 • CD144 • CD146 • CD147 • CD148 • CD150 ... 2001). „Tissue distribution of the human CD97 EGF-TM7 receptor". Tissue Antigens. 57 (4): 325-31. PMID 11380941. doi:10.1034/j. ... Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of ...
Tissue Antigens (англ.)русск. : journal. - 2007. - Vol. 68, no. 6. - P. 509-517. - DOI:10.1111/j.1399-0039.2006.00726.x. - PMID ...
1991). „Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow". Blood. 78 (1): 30-7. PMID ... CD137 • CD138 • CD140b • CD141 • CD142 • CD143 • CD144 • CD146 • CD147 • CD148 • CD150 ... 2003). „Signal transduction-associated and cell activation-linked antigens expressed in human mast cells". Int. J. Hematol. 75 ...
Seligman P. A., Butler C. D., Massey E. J., etal. The p97 antigen is mapped to the q24-qter region of chromosome 3; the same ... Le Beau M. M., Diaz M. O., Plowman G. D., etal. Chromosomal sublocalization of the human p97 melanoma antigen. (англ.) // Hum. ... Plowman G. D., Brown J. P., Enns C. A., etal. Assignment of the gene for human melanoma-associated antigen p97 to chromosome 3 ... Rose T. M., Plowman G. D., Teplow D. B., etal. Primary structure of the human melanoma-associated antigen p97 ( ...
CD137 • CD138 • CD140b • CD141 • CD142 • CD143 • CD144 • CD146 • CD147 • CD148 • CD150 ... 1996). "CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human ...
... is a co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells. The ... Leucocyte typing: human leucocyte differentiation antigens detected by monoclonal antibodies: specification, classification, ... T cells displaying CD4 molecules (and not CD8) on their surface, therefore, are specific for antigens presented by MHC II and ... CD1+Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) ...
1997). "The Oka blood group antigen is a marker for the M6 leukocyte activation antigen, the human homolog of OX-47 antigen, ... 1992). "Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse ... Kasinrerk W, Fiebiger E, Stefanová I, Baumruker T, Knapp W, Stockinger H (1992). "Human leukocyte activation antigen M6, a ... Ok blood group system at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH ...
In addition to aiding with cytotoxic T cell antigen interactions the CD8 co-receptor also plays a role in T cell signaling. The ... the CD8 co-receptor plays a role in T cell signaling and aiding with cytotoxic T cell antigen interactions. ... This affinity keeps the T cell receptor of the cytotoxic T cell and the target cell bound closely together during antigen- ... Once the T cell receptor binds its specific antigen Lck phosphorylates the cytoplasmic CD3 and ζ-chains of the TCR complex ...
CD74 (англ. HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain) - мембранный белок ... II histocompatibility antigen gamma chaingamma chain of class II antigensIiHLA-DR antigens-associated invariant chainIa antigen ... Riberdy J.M., Newcomb J.R., Surman M.J., Barbosa J.A., Cresswell P. HLA-DR molecules from an antigen-processing mutant cell ... Machamer C.E., Cresswell P. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens (англ.) // ...
van Rhenen A., van Dongen G. A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination ...
A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... antigen processing and presentation of exogenous peptide antigen via MHC class II. ... antigen binding. • transmembrane signaling receptor activity. • MHC class II protein binding. Cellular component. • membrane. • ...
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a ... 2001). "Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells". J. Biol. Chem. 276 ( ... CEACAM5, CD66e, CEA, carcinoembryonic antigen related cell adhesion molecule 5. External IDs. HomoloGene: 128801 GeneCards: ... Oikawa S, Nakazato H, Kosaki G (1987). "Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence". ...
In humans, the CD44 antigen is encoded by the CD44 gene on Chromosome 11.[5] CD44 has been referred to as HCAM (homing cell ... The CD44 antigen is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. ... Indian blood group system at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH ... "Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in ...
It is also called Lewis x and SSEA-1 (stage-specific embryonic antigen 1) and represents a marker for murine pluripotent stem ... CD15 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) ... CD15 (3-fucosyl-N-acetyl-lactosamine) is a cluster of differentiation antigen - an immunologically significant molecule. CD15 ...
B cells can present antigens to a specialized group of helper T cells called TFH cells. If an activated TFH cell recognizes the ... Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help". Journal of Immunology. 149 (12): ... It binds to CD40 (protein) on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In ... Grewal, IS; Xu, J; Flavell, RA (7 December 1995). "Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand". ...
Eichler W, Hamann J, Aust G (Nov 1997). "Expression characteristics of the human CD97 antigen". Tissue Antigens. 50 (5): 429-38 ... Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC, Tak PP (Apr 1999). "Expression of the activation antigen CD97 and ... Tissue Antigens. 57 (4): 325-31. doi:10.1034/j.1399-0039.2001.057004325.x. PMID 11380941.. ... "Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of ...
... uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate (англ.) // Blood (англ ...
2000). "Characterization of a new member of the TNF family expressed on antigen presenting cells.". Biol. Chem. 380 (12): 1443- ... CD137 • CD138 • CD140b • CD141 • CD142 • CD143 • CD144 • CD146 • CD147 • CD148 • CD150 ... "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.". Semin ...
Macrophage-1 antigen (CD11b+CD18). *VLA-4 (CD49d+CD29). *Glycoprotein IIb/IIIa (ITGA2B+ITGB3) ...
The protein also carries the Jr(a) antigen, which defines the Junior blood group system.[9] ...
"Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and ...
... antigen je protein koji je kod ljudi kodiran CD97 genom.[1][2][3] ... CD137 • CD138 • CD140b • CD141 • CD142 • CD143 • CD144 • CD146 • CD147 • CD148 • CD150 ... 2001). "Tissue distribution of the human CD97 EGF-TM7 receptor". Tissue Antigens 57 (4): 325-31. PMID 11380941. doi:10.1034/j. ... "Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of ...
"Entrez Gene: ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)".. *^ May, K. E.; Villar, J.; Kirtley, S.; ... CD61+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ...
"Direct association of adenosine deaminase with a T cell activation antigen, CD26". Science. 261 (5120): 466-9. doi:10.1126/ ...
antigen processing and presentation of peptide antigen via MHC class I. • antigen processing and presentation of exogenous ... antigen processing and presentation of exogenous peptide antigen via MHC class I. • lipoprotein transport. • negative ... peptide antigen via MHC class I, TAP-dependent. • platelet degranulation. • MyD88-dependent toll-like receptor signaling ...
Primarily, the VCAM-1 protein is an endothelial ligand for VLA-4 (Very Late Antigen-4 or integrin α4β1) of the β1 subfamily of ...
antigen binding. • virus receptor activity. • protein binding. • transmembrane signaling receptor activity. • identical protein ...
T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell. • T cell antigen ... CD137 · CD138 · CD140b · CD141 · CD142 · CD143 · CD144 · CD146 · CD147 · CD148 · CD150 ...
CD137 antigenImported. ,p>Information which has been imported from another database using automatic procedures.,/p> ,p>,a href ... tr,Q3U3R1,Q3U3R1_MOUSE CD137 antigen OS=Mus musculus OX=10090 GN=Tnfrsf9 PE=2 SV=1 ...
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. ... Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. ... CD137) regress due to enhanced tumor antigen-specific cytotoxic T lymphocyte responses. In this study, we demonstrate that ... We provide evidence that immunological ignorance, rather than anergy or deletion, of tumor antigen-specific CTLs during the ...
Tumor necrosis factor receptor superfamily member 9, 4-1BB ligand receptor, T-cell antigen 4-1BB, CD137. ...
CD137 Ligand, TNFSF9 binds to 4-1BBR also called 4-1bb Receptor and CD137, TNFRSF9. 4-1BBL stimulates the growth of activated ... CD137 increases immune activity to remove tumors in mice. TRAF adaptor proteins bind to CD137 and transduce the signals which ... 4-1BBL also called 4-1BB Ligand and CD137L, CD137 Ligand, TNFSF9 binds to 4-1BBR also called 4-1bb Receptor and CD137, TNFRSF9 ... 4-1BBL antigen is a type 2 transmembrane glycoprotein which is part of the TNF superfamily that is expressed on activated T ...
Conclusions: HER2 x CD137 and EphA2 x CD137 DART proteins promote T-cell co-stimulation in a tumor antigen-dependent manner and ... lines expressing HER2 or EphA2 revealed tumor antigen-dependent CD137 pathway activation by HER2 x CD137 and EphA2 x CD137 DART ... Abstract 3642: Tumor-antigen expression-dependent activation of the CD137 costimulatory pathway by bispecific DART® proteins. ... Tumor-antigen expression-dependent activation of the CD137 costimulatory pathway by bispecific DART® proteins [abstract]. In: ...
and CD137 expression by FACS (. ). B, CD3+ CD8+ CD137+ cells were sorted by FACS and expanded in vitro, and the resulting T- ... CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol ... Initial screening of TILs for recognition of mutated antigens. Both IFNγ enzyme-linked immunospot (ELISPOT) assay and CD137 ... CD137 is transiently expressed on T cells that have recently been activated by TCR engagement (20), and expression of CD137 on ...
CD137/4-1BB (Tumor necrosis factor receptor superfamily member 9, T-cell antigen 4-1BB homolog, T-cell antigen ILA). CD137 (ILA ... The expression of CD137 is strictly activation dependent in primary cells. Co-stimulation through CD137 enhances T lymphocyte ... While cross-linking of CD137 activates T lymphocytes, cross-linking of the CD137 ligand has the opposite effect. This reverse ... T-cell antigen 4-1BB homolog, T-cell antigen ILA) ... The expression of CD137 isoforms in lymphocytes has been shown ...
Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major barrier to use of these cells for ... We uncovered a previously unrecognized, antigen-independent effect of CARs expressing the CD137 cytoplasmic domain that likely ... Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major barrier to use of these cells for ... Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic ...
Browse our 4-1BB/TNFRSF9/CD137 Peptides and Proteins all backed by our Guarantee+. ... 4-1BB/TNFRSF9/CD137 Peptides and Proteins available through Novus Biologicals. ... 4-1BB/TNFRSF9/CD137 protein, TNFRSF9 protein, 4-1BB ligand receptor protein, 4-1BB protein, CD137 antigen protein, CD137MGC2172 ... 4-1BB/TNFRSF9/CD137 Proteins. We offer 4-1BB/TNFRSF9/CD137 Peptides and 4-1BB/TNFRSF9/CD137 Proteins for use in common research ...
Hamster Monoclonal CD137 antibody [17B5] (Low endotoxin, azide free). Validated in FACS, Functional Assay. Tested in Mouse. - ... Antigen Species Mouse Purification Protein G purified. From tissue culture supernatant Conjugation Unconjugated. ... Tumor Necrosis Factor Receptor Superfamily, Member 9,4-1Bb,A930040I11Rik,Aa408498,Ai325004,Cdw137,Cd137,Ila,Ly63,Tnfrsf9 ...
Shop a large selection of products and learn more about Thermo Scientific Lab Vision CD137 (4-1BB) Ab-1, Mouse Monoclonal ... Antigen. CD137 Ab-1. Classification. Monoclonal. Concentration. 200μg/mL. Format. Concentrated. ... 4-1BB (also known as CD137) is an inducible receptor-like protein expressed on the cell surface of activated splenic T cells ... Ensure accurate, reproducible results in immunofluorescence and flow cytometry applications with Thermo Scientific CD137 (4-1BB ...
CD137neg counterparts did not respond (Fig. 3B and C). CD137 upregulation was antigen-driven because CD137pos and CD137neg TILs ... and CD137negPD-1+ TIL subsets revealed a dichotomy in tumor antigen-specific reactivity. CD137posPD-1+ and CD137posPD-1neg TILs ... For specific antigen stimulation of isolated CD137pos and CD137neg T cells, 106 T2 cells were loaded with 1 μmol/L MART-1:26-35 ... CD137pos and CD137neg fractions were isolated and rested in media for 10 days. CD137pos, CD137neg, or nonmanipulated TILs were ...
Recombinant Mouse CD137 protein (Tagged) (Biotin) is a HEK 293 Protein fragment 24 to 187 aa range, ,=90% purity and validated ... T cell antigen 4 1BB homolog. *T cell antigen ILA. *T-cell antigen 4-1BB homolog ... Recombinant Mouse CD137 protein (Tagged) (Biotin). See all CD137 proteins and peptides. ...
Mouse monoclonal CD137 antibody [4B4-1] conjugated to PE. Validated in Flow Cyt and tested in Human, Non human primates. ... T cell antigen 4 1BB homolog antibody. *T cell antigen ILA antibody ... Anti-CD137 antibody [4B4-1], prediluted (PE). See all CD137 primary antibodies. ... Primary - Mouse Anti-CD137 antibody [4B4-1], prediluted (PE) (ab200561) Flow Cyt ...
Positive test for hepatitis B surface antigen (HBsAg). *Positive test for qualitative hepatitis C viral load (by PCR) (Note: ... Experimental: A2 Anti-CD137 (Urelumab) Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats ... Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18). The safety ... Experimental: B2 Anti-CD137 + Anti-PD-1 Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti- ...
Neoantigen-reactive T cells were enriched from TILs by sorting for CD137+ CD8+ T cells and expanded in vitro. Dominant TCR α ... Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 ... Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 ... Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 ...
Mouse Monoclonal Anti-4-1BB/TNFRSF9/CD137 Antibody (145501) [Alexa Fluor® 750]. Validated: Flow. Tested Reactivity: Human. 100 ... The natural ligand, 4-1BBL, is a member of the TNF superfamily and is expressed on activated antigen presenting cells including ... Home » 4-1BB/TNFRSF9/CD137 » 4-1BB/TNFRSF9/CD137 Antibodies » 4-1BB/TNFRSF9/CD137 Antibody (145501) [Alexa Fluor® 750] ... Blogs on 4-1BB/TNFRSF9/CD137. There are no specific blogs for 4-1BB/TNFRSF9/CD137, but you can read our latest blog posts. ...
Rapid identification and sorting of viable virus-reactive CD4+ and CD8+ T cells based on antigen-triggered CD137 expression. J ... Membrane-bound CD137 has been used to detect Ag-reactive T cells (21), and CD137+ cells could be detected after CMV Ag ... or without anti-CD40 to stain for CD137 (J-O). At 6 and 24 h CMV Ag stimulation, CD154 (A-D) or CD137 (J-M) expression (black ... and CD137-expressing cells, respectively. Percentages of CD154 or CD137, induced by CMV Ag-loaded autologous CFSE-labeled PBMCs ...
The cytometric enumeration and characterization of antigen-specific lymphocytes, as introduced about 15 years ago, has ... Keywords: CD137; CD154; MACS; MHC multimer; antigen-specific T cells; cytokine secretion assay; flow-cytometry; rare cells; ... due to the low frequency of certain antigen-specific lymphocyte subsets and the complexity of T cell antigen recognition. This ... Flow-cytometric analysis of rare antigen-specific T cells Cytometry A. 2013 Aug;83(8):692-701. doi: 10.1002/cyto.a.22317. Epub ...
Therapeutic vaccination with tumor cells that engage CD137. Karl Erik Hellstrom, Ingegerd Hellstrom ... Antigen-Specific CD8 T Cells Can Eliminate Antigen-Bearing Keratinocytes with Clonogenic Potential via an IFN-γ-Dependent ... Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. L P Chen, E K Thomas, S L Hu, I Hellström, K E ... Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. L P Chen, E K Thomas, S L Hu, I Hellström, K E ...
tumor necrosis factor receptor superfamily,member 9,cell differentiation antigen CD137 (4-1BB),expressed on B and T cells, ... Suggested Antigen Peptide Sequences for TNFRSF9 Gene. GenScript: Design optimal peptide antigens:. *T-cell antigen ILA (TNR9_ ... orf clones - Search results for 169 available CD137 gene related products * Overview of 169 available CD137 gene related ... orf clones - Search results for 169 available CD137 gene related products * Overview of 169 available CD137 gene related ...
Priming of CD137+ PD-1+ Antigen-Specific TILs by Activated BATF3-Dependent DCs. We hypothesized that expansion and activation ... 3B). Notably, antigen-specific TILs showed higher surface expression of PD-1 and CD137 compared with the bulk of CD8+ ... In WT mice, treatment with anti-CD137 mAb increased the frequency and numbers of tumor antigen-specific CD8+ T cells from the ... sFLT3L and poly-ICLC induce a BATF3-dependent increase in the numbers of tumor-antigen-specific TILs expressing CD137 and PD-1 ...
... expression levels of antigen genes and protease cleavage signatures. Because it leverages these diverse training data and our ... a multimodal recurrent neural network for predicting the likelihood of antigen presentation from a gene of interest in the ... Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II molecules would be valuable for vaccine ... Antigen-specific T-cell activation was evaluated by cell surface CD137 induction. For 2 of 3 patients (MCL005 and MCL052), ...
4-1BBL (4-1BB ligand) is found on APCs (antigen presenting cells) and binds to 4-1BB. ... CD137. References[edit]. *^ Lotze, Michael (2001). Dendritic Cells. Boston: Academic Press. ISBN 0-12-455851-8.. ...
i,The present invention provides pharmaceutical compositions of such antigens and/or vac ... The present invention provides antigens and vaccines useful in prevention of infection by ,i,Yersinia pestis. ,/ ... CD137 agonists to treat patients with IgE-mediated conditions. July, 2008. Pluenneke. ... Production of Yersinia pestis Antigens. In accordance with the present invention, Y. pestis antigens (including Y. pestis ...
The interaction of CD137 with its ligand, 4-1BBL, on antigen presenting cells (APCs) delivers a bidirectional costimulatory ... CD137 engagement is shown to be required for CD8+ T cell survival and memory formation. The monoclonal antibody 17B5 is ... Clone 17B5 reacts with mouse CD137, also known as 4-1BB or TNFRSF9, a member of the TNFR superfamily. It is expressed on the ... The interaction of CD137 with its ligand, 4-1BBL, on antigen presenting cells (APCs) delivers a bidirectional costimulatory ...
... regulation of CD137-signalosomes assembly and disassembly will be key to improve the therapeutic activities of chimeric antigen ... Working in a coordinated fashion, these CD137-signalosomes will ultimately promote CD137-mediated T cell proliferation and ... Working in a coordinated fashion, these CD137-signalosomes will ultimately promote CD137-mediated T cell proliferation and ... family of adaptor proteins to build the CD137 signalosome for transducing signals into the cell. Thus, upon CD137 activation by ...
CD137) to those against tumor antigens (e.g. EphA2 or Nectin-4). EphA2-targeted Bicycle toxin conjugate BT5528 gives rise to ... Nectin-4 targeted CD137 TICA is a potent agonist that activates costimulatory receptors selectively in the presence of tumor ... Treatment of tumor antigen -expressing tumors in immunocompetent mice with TICAs lead to profound reprogramming of the tumor ...
CD137) to those against tumor antigens (e.g. EphA2 or Nectin-4). EphA2-targeted Bicycle toxin conjugate BT5528 gives rise to ... Nectin-4 targeted CD137 TICA is a potent agonist that activates costimulatory receptors selectively in the presence of tumor ... Treatment of tumor antigen -expressing tumors in immunocompetent mice with TICAs lead to profound reprogramming of the tumor ...
... proliferating cell nuclear antigen.; PLKO.1‐shGFP, PLKO.1‐short hairpin GFP; PLKO.1‐shNFATc1, PLKO.1‐short hairpin NFATc1 ... TNF‐α Stimulates CD137 Expression in ECs. Since the expression of CD137 was low in normal ECs, we first stimulated CD137 ... Blocking CD137 signaling with inhibitory anti‐CD137 antibody could inhibit this activation and attenuated agonist anti‐CD137 ... we activated the CD137 signaling by agonist anti‐CD137 antibody and inhibited it by inhibitory anti‐CD137 antibody. We found ...
  • The adoptive transfer of normal peripheral blood lymphocytes (PBL) genetically modified by the insertion of tumor-reactive T-cell receptors (TCR) or chimeric antigen receptors (CAR) can mediate tumor regression in multiple histologies ( 1-7 ). (aacrjournals.org)
  • Persistence of T cells engineered with chimeric antigen receptors (CARs) has been a major barrier to use of these cells for molecularly targeted adoptive immunotherapy. (nih.gov)
  • Understanding the composition and fine regulation of CD137-signalosomes assembly and disassembly will be key to improve the therapeutic activities of chimeric antigen receptors (CARs) encompassing the CD137 cytoplasmic domain and a new generation of CD137 agonists for the treatment of cancer. (frontiersin.org)
  • A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. (springer.com)
  • The antagonistic mAbs used in immune checkpoint blockade are able to block T cell-inhibitory signaling from receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), and have been successfully used in the treatment of several types of cancers ( 1 ). (frontiersin.org)
  • The engagement of 4-1BB by its ligand or agonistic mAbs provides substantial boosts to the T cell response ( 4 ), which prompted the incorporation of 4-1BB intracellular signaling domain into TCR-like chimeric antigen receptors (CARs) and ultimately greatly improved their functionality ( 5 ). (frontiersin.org)
  • Viral vectors have been used to genetically modify in vitro expanded NK cells to express chimeric antigen receptors (CARs), which confer cytotoxicity against tumors. (plos.org)
  • Further, expression of anti-CD19 chimeric antigen receptors (CARs) containing 41BB and CD3ζ signal domains on NK cells enhanced the activating signals originating from CD19 antigen engagement, leading to cytotoxicity specifically against B-cell leukemia [4] . (plos.org)
  • Therefore, neoantigens represent an important class of tumour-specific, tumour rejection antigens, which can be targeted by neoantigen-specific T cell receptors (TCRs). (springer.com)
  • Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR chain. (springermedizin.de)
  • Second generation CARs had a more potent signaling domain from various co-stimulatory receptors such as CD28 or CD137 (4-1BB). (jcancer.org)
  • The inflammatory cascade is triggered by cross talk between T cells and macrophages, and interaction of cell surface receptors (e.g., antigen receptor and costimulatory receptors) with their counterpart ligands is involved in this cross talk ( 8 ). (diabetesjournals.org)
  • Chimeric antigen receptors (CAR) are molecules composed of an extracellular antigen-binding domain derived from the immunoglobulin variable chain (scFv) linked to intracellular T-cell activating and costimulatory domains ( 5, 6 ). (aacrjournals.org)
  • Another approach relies upon the use of chimeric antigen receptors (CARs) that confer T cells with the MHC-independent specificity of a tumor antigen-specific antibody and potent T cell activity delivered by TCR and costimulatory domains. (upenn.edu)
  • Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. (cusabio.com)
  • As a consequence, agonist antibodies exert potent antitumour effects in mouse models and the CD137 signalling domain is critical in chimeric antigen receptors (CAR) of CAR T cells approved to be used in the clinic. (cun.es)
  • CD antigens for cluster of differentiation, which indicates a defined subset of cellular surface receptors (epitopes) that identify cell type and stage of differentiation, and which are recognized by antibodies. (sinobiological.com)
  • Non peptide antigen presentation to T-cell receptors on NKT cells. (sinobiological.com)
  • 4-1BBL also called 4-1BB Ligand and CD137L, CD137 Ligand, TNFSF9 binds to 4-1BBR also called 4-1bb Receptor and CD137, TNFRSF9. (prospecbio.com)
  • TNFSF9 and TNFRSF9 take part in the antigen demonstration development and in the induction of cytotoxic T cells. (prospecbio.com)
  • We offer 4-1BB/TNFRSF9/CD137 Peptides and 4-1BB/TNFRSF9/CD137 Proteins for use in common research applications: ELISA, Functional, Protein Array, SDS-Page, Western Blot. (novusbio.com)
  • Each 4-1BB/TNFRSF9/CD137 Peptide and 4-1BB/TNFRSF9/CD137 Protein is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. (novusbio.com)
  • Our 4-1BB/TNFRSF9/CD137 Peptides and 4-1BB/TNFRSF9/CD137 Proteins can be used in a variety of model species: Human. (novusbio.com)
  • Choose from our 4-1BB/TNFRSF9/CD137 Peptides and Proteins. (novusbio.com)
  • There are currently no images for 4-1BB/TNFRSF9/CD137 Antibody (FAB838S). (novusbio.com)
  • Detects human 4‑1BB/TNFRSF9/CD137 in direct ELISAs and Western blots. (novusbio.com)
  • It is alternatively known as TNFRSF9, CD137, and ILA. (novusbio.com)
  • Clone 17B5 reacts with mouse CD137, also known as 4-1BB or TNFRSF9, a member of the TNFR superfamily. (miltenyibiotec.com)
  • We previously reported that CD137 (encoded by Tnfrsf9 ) deficiency suppressed type 1 diabetes (T1D) progression in NOD mice. (jimmunol.org)
  • Tnfrsf9 −/− CD8 T cells had significantly reduced diabetogenic capacity, whereas absence of CD137 in non-T and non-B cells had a limited impact on T1D progression. (jimmunol.org)
  • CD137 (the protein product of Tnfrsf9 ) in NOD mice is hypofunctional. (jimmunol.org)
  • One such TNFRSF member, 4-1BB (CD137, TNFRSF9) ( 3 ), forms the basis for the immunostimulatory approach used in this article. (frontiersin.org)
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. (researchandmarkets.com)
  • Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 28 molecules. (researchandmarkets.com)
  • The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. (researchandmarkets.com)
  • It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects. (researchandmarkets.com)
  • As a member of the tumor necrosis factor receptor superfamily (TNFRSF9) expressed on immune cells, 4-1BB/CD137 provides a bidirectional inflammatory signal through binding to its ligand 4-1BBL. (diabetesjournals.org)
  • As a member of the TNF receptor superfamily (TNFRSF9) expressed on the cell surface, 4-1BB/CD137 provides a costimulatory signal through binding to its ligand 4-1BBL (CD137L/TNFRSF9). (diabetesjournals.org)
  • CD137 (4-1BB) is a surface glycoprotein that belongs to the tumour necrosis factor receptor family (TNFRSF9). (cun.es)
  • The absence of 4-1BBR in murine subjects demonstrate augmented T cell activation, which results due to the lack of CD137 in regulatory T cells. (prospecbio.com)
  • Introduction: CD137 (4-1BB) is a co-stimulatory molecule expressed by activated T and NK cells that, upon interaction with its CD137 ligand, further supports cell activation, proliferation and survival. (aacrjournals.org)
  • Co-stimulatory activity was characterized with primary human T cells in the presence or absence of tumor target antigen-expressing cells. (aacrjournals.org)
  • No T-cell co-stimulation was observed by either DART molecule in the absence of antigen-expressing tumor cells. (aacrjournals.org)
  • Consistent with the preferential induction of CD137 by the CD8 T cell subset, CD137-based DART proteins induced a substantial increase in the fraction of CD8 + central memory and effector memory T cells in the presence of the proper tumor antigen expressing cells. (aacrjournals.org)
  • TILs were cultured with autologous dendritic cells (DC) transfected with in vitro transcribed (IVT) mRNAs encoding TMGs and were evaluated for IFNγ secretion and CD137 expression. (aacrjournals.org)
  • Neoantigen-reactive T cells were enriched from TILs by sorting for CD137 + CD8 + T cells and expanded in vitro . (aacrjournals.org)
  • Somatic mutations in tumor cells can be recognized by tumor-infiltrating lymphocytes (TIL), and these appear to be the target antigens that result in cancer regression following adoptive cell transfer (ACT) with TIL. (aacrjournals.org)
  • The expression of CD137 is strictly activation dependent in primary cells. (biovendor.com)
  • 4-1BB (also known as CD137) is an inducible receptor-like protein expressed on the cell surface of activated splenic T cells and thymocytes. (fishersci.com)
  • Upregulation of CD137 (4-1BB) on recently activated CD8 + T cells has been used to identify rare viral or tumor antigen-specific T cells from peripheral blood. (aacrjournals.org)
  • TILs from resected ovarian cancer or melanoma were measured for surface CD137 expression directly or after overnight incubation in the presence of tumor cells and homeostatic cytokines. (aacrjournals.org)
  • Fresh ovarian TILs and TALs naturally expressed higher levels of CD137 than circulating T cells. (aacrjournals.org)
  • Enriched CD137 pos TILs, but not PD-1 pos or PD-1 neg CD137 neg cells, possessed autologous tumor reactivity in vitro and in vivo . (aacrjournals.org)
  • In melanoma studies, all MART-1-specific CD8 + TILs upregulated CD137 expression after incubation with HLA-matched, MART-expressing cancer cells and antigen-specific effector function was restricted to the CD137 pos subset in vitro . (aacrjournals.org)
  • Here we review the current technologies for the analysis of antigen specific T cells within the physiologic T cell repertoire and with a special focus on recent technologies addressing the analysis of rare antigen-specific T cell populations including naive and regulatory T cells. (nih.gov)
  • The natural ligand, 4-1BBL, is a member of the TNF superfamily and is expressed on activated antigen presenting cells including dendritic cells, macrophages, and B cells. (novusbio.com)
  • High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4 + T cells in human melanoma. (nature.com)
  • 4-1BBL (4-1BB ligand) is found on APCs (antigen presenting cells) and binds to 4-1BB. (wikipedia.org)
  • Using Batf3 −/− mice, which are defective for cross-presentation of cell-associated antigens, we show that BATF3-dependent dendritic cells (DC) are essential for the response to therapy with anti-CD137 or anti-PD-1 mAbs. (aacrjournals.org)
  • The interaction of CD137 with its ligand, 4-1BBL, on antigen presenting cells (APCs) delivers a bidirectional costimulatory signal. (miltenyibiotec.com)
  • Working in a coordinated fashion, these CD137-signalosomes will ultimately promote CD137-mediated T cell proliferation and survival and will endow T cells with stronger effector functions. (frontiersin.org)
  • CD137 (4‐1BB), a well‐known costimulatory molecule, has been demonstrated to express in both human atherosclerotic plaques 3 and the endothelial cells of mouse atherosclerotic lesions upon stimulation by tumor necrosis factor‐α (TNF‐α). (ahajournals.org)
  • 5 We also demonstrated that the nuclear factor of activated T cells 1 (NFATc1) is the critical factor linking CD137 signaling to the progression of atherosclerotic plaques. (ahajournals.org)
  • Incorporation of the CD137 signaling domain specifically reprogrammed cells for multifunctional cytokine secretion and enhanced persistence of T cells. (pnas.org)
  • Genetically redirected T cells have promise of targeting T lymphocytes to tumor antigens, confer resistance to the tumor microenvironment, and providing immunosurveillance. (pnas.org)
  • Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. (springer.com)
  • Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. (springer.com)
  • Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. (springer.com)
  • Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. (springer.com)
  • We also demonstrated that soluble CD137 produced by regulatory T cells contributed to their autoimmune-suppressive function in this model. (jimmunol.org)
  • We further demonstrated that CD137 was important for the accumulation of β cell-autoreactive CD8 T cells but was dispensable for their activation in pancreatic lymph nodes. (jimmunol.org)
  • This suggests that increased precursor frequency of β cell-autoreactive CD8 T cells in NY8.3 mice obviated a role for CD137 in diabetogenesis. (jimmunol.org)
  • Collectively, our results indicate that one important diabetogenic function of CD137 is to promote the expansion and accumulation of β cell-autoreactive CD8 T cells, and in the absence of CD137 or its interaction with CD137 ligand, T1D progression is suppressed. (jimmunol.org)
  • Expression of CD137 is induced on activated T cells, and it interacts with CD137 ligand (CD137L) expressed on APCs. (jimmunol.org)
  • In addition to T cells, CD137 is also expressed on myeloid cells and activated NK cells to elicit various immune-modulating functions ( 9 , 10 ). (jimmunol.org)
  • NOD T cells stimulated via CD137 proliferated less, and produced significantly lower levels of IL-2, than those isolated from the B10-derived Idd9.3 congenic strain (NOD. (jimmunol.org)
  • Are Chimeric Antigen Receptor (CAR)-T Cells Ready for Prime Time in Prostate Cancer? (urotoday.com)
  • These engineered cells have the ability to identify antigens in a major histocompatibility complex (MHC)-independent manner, unlike unmodified T cells that require T cell receptor (TCR)-mediated antigen recognition. (urotoday.com)
  • It is only expressed and present on T cells for a short interval occurring after TCR engagement, and has a single identified ligand, 4-1BBL, found on antigen presenting cells ( 4 ). (frontiersin.org)
  • Because tumor cells, among others, are killed by cytotoxic T lymphocytes (CTL) in an antigen-specific manner, agents that promote CD8+ T-cell activation and impart strong cytolytic and inflammatory properties, as well as antigen specificity, are ideal candidates for enhancing tumor-antigen-specific immunity. (aacrjournals.org)
  • Immunotherapy targeting CD8+ T cells with agonistic anti-4-1BB (CD137) monoclonal antibody (mAb) fulfills these requirements because 4-1BB-mediated signals are biased toward CD8+ T cells, promoting their survival, differentiation, and acquisition of potent cytolytic properties ( 1 ). (aacrjournals.org)
  • CD137 is expressed by activated T cells of both the CD4+ and CD8+ lineages. (wikipedia.org)
  • Although it is thought to function mainly in co-stimulating those cell types to support their activation by antigen presenting cells expressing its ligand (CD137L), CD137 is also expressed on dendritic cells, B cells, NK cells, neutrophils and macrophages. (wikipedia.org)
  • The best characterized activity of CD137 is its costimulatory activity for activated T cells. (wikipedia.org)
  • MHC class I-related molecule MR1 presents riboflavin- and folate-related metabolites to mucosal-associated invariant T cells, but it is unknown whether MR1 can present alternative antigens to other T cell lineages. (elifesciences.org)
  • These data extend the role of MR1 beyond microbial antigen presentation and indicate MR1T cells are a normal part of the human T cell repertoire. (elifesciences.org)
  • CD19 is an ideal target antigen for immunotherapy because it is expressed on nearly all leukemia cells in most patients with B-cell acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL) [13] , [14] . (plos.org)
  • Adoptive transfer of T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory populations. (bloodjournal.org)
  • Complete remission (CR) rates as high as 90% have been reported in children and adults with relapsed and refractory ALL treated with CAR-modified T cells targeting the B-cell-specific antigen CD19. (bloodjournal.org)
  • Chimeric antigen receptor (CAR)-modified T cells targeting CD19, the best-studied CAR T-cell therapy to date, will be discussed, with a focus on clinical trials for ALL demonstrating efficacy as well as toxicity and toxicity management. (bloodjournal.org)
  • CD27: This molecule supports antigen-specific expansion of naïve T cells and is vital for the generation of T cell memory. (wikipedia.org)
  • CD40: This molecule, found on a variety of immune system cells including antigen presenting cells has CD40L, otherwise known as CD154 and transiently expressed on the surface of activated CD4+ T cells, as its ligand. (wikipedia.org)
  • CD137-mediated signaling is also known to protect T cells, and in particular, CD8+ T cells from activation-induced cell death. (wikipedia.org)
  • OX40's value as a drug target primarily lies in the fact that, being transiently expressed after T-cell receptor engagement, it is only upregulated on the most recently antigen-activated T cells within inflammatory lesions. (wikipedia.org)
  • The ligand for GITR is mainly expressed on antigen presenting cells. (wikipedia.org)
  • Signaling by 4-1BB Receptor has been implicated in the antigen-presentation process and generation of cytotoxic T cells. (biovendor.com)
  • We engineered human T cells to express a chimeric autoantibody receptor (CAAR), consisting of the PV autoantigen, desmoglein (Dsg) 3, fused to CD137-CD3ζ signaling domains. (sciencemag.org)
  • AGEN1223, a bispecific antibody designed to selectively deplete immunosuppressive T regulatory cells from the tumor microenvironment by taking advantage of co-expression of the target antigens specifically on tumor-infiltrating T regulatory cells. (genengnews.com)
  • AGEN2373, a CD137 agonist designed to boost the immune response to cancer cells by enhancing CD137 co-stimulatory signaling in activated immune cells. (genengnews.com)
  • These tumor cells express stress-induced molecules such as surface calreticulin, tumor antigens in context of MHC class I molecules, and/or NKG2D ligands recognized by CD8 + effector cells and NK cells, respectively. (nih.gov)
  • DCs can also take up and cross-present tumor antigens to T cells including NKT cells (glycolipid antigens presenting via CD1d). (nih.gov)
  • Effector T cells express co-stimulatory molecules such as CD28, CD137, GITR, OX40 that enhance their proliferation and survival. (nih.gov)
  • An effective vaccine must stimulate coordinated T cell responses, but the large size of the genome and the low frequency of HSV-1-specific T cells have hampered the search for the most effective T cell antigens for inclusion in a candidate vaccine. (eur.nl)
  • We used cross-presentation and CD137 activation-based FACS to enrich for polyclonal CD8+T effector T cells. (eur.nl)
  • In this era of microbial genomics, our methods - also demonstrated in principle for vaccinia virus for both CD8+and CD4+T cells - should be broadly applicable to the selection of T cell antigens for inclusion in candidate vaccines for many pathogens. (eur.nl)
  • The BCM uses a coupled system of non-linear differential equations to describe the dynamics of Antigen Presenting Cells, Natural Killer and T Cells together with the interpheron (IFN)-γ and tumor necrosis factor (TNF)-α levels in the media culture. (doaj.org)
  • Bayes factors provided decisive evidence favoring direct CD137 signaling on T cells. (doaj.org)
  • Moreover, the posterior distribution of the parameters that describe the CD137 signaling showed that the regulation of IFN-γ levels is based more on T cells survival than on direct induction. (doaj.org)
  • Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. (rcsb.org)
  • CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). (researchandmarkets.com)
  • FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of mature T-cells. (researchandmarkets.com)
  • CD137 is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. (acris-antibodies.com)
  • Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. (acris-antibodies.com)
  • Screening of patient tumor-derived expression libraries with autologous tumor-reactive CD4 + or CD8 + T cells revealed two categories of spontaneously recognized T cell antigens: (i) nonmutated proteins with tumor-associated expression and (ii) mutated gene products ( 7 ). (sciencemag.org)
  • To facilitate adoptive immunotherapy, we applied genetically-engineered K562 cell-based artificial antigen presenting cells (aAPCs) for the direct and rapid expansion of TILs isolated from primary cancer specimens. (biomedcentral.com)
  • aAPC-expanded TILs undergo numerical expansion of tumor antigen-specific cells, remain amenable to secondary aAPC-based expansion, and have low CD4/CD8 ratios and FOXP3+ CD4+ cell frequencies. (biomedcentral.com)
  • Artificial antigen presenting cells (aAPCs) expressing ligands for the T cell receptor and costimulatory molecules can activate and expand T cells for transfer, while improving their potency and function. (biomedcentral.com)
  • These cells could directly recognize tumor cells by genetic modification to express a chimeric antigen receptor (CAR), and they were activated to exhibit a durable persistence in vivo through the T-cell activation endodomain with costimulatory signaling molecules [ 1 , 2 ]. (hindawi.com)
  • Recent published clinical studies on CART cells specific for solid tumor antigens. (hindawi.com)
  • Current status of clinical trials of chimeric antigen receptor-modified T (CART) cells in malignancies. (hindawi.com)
  • Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tumor-associated antigens (TAAs) expressing on tumor cell surface. (springermedizin.de)
  • Current studies demonstrated that various TAAs could act as target antigens for CAR-T cells, for instance, the type III variant epidermal growth factor receptor (EGFRvIII) was considered as an ideal target for its aberrant expression on the cell surface of several tumor types. (springermedizin.de)
  • Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. (springermedizin.de)
  • Di S, Li Z. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. (springermedizin.de)
  • Gene transfer techniques have now been developed to genetically modify T cells to confer novel antigen specificity by stably expressing a chimeric antigen receptor (CAR) on their surface. (jcancer.org)
  • When antigen is encountered, CAR-modified T cells become activated and kill in an antigen dependent, but HLA independent manner, making this an attractive approach as a generalized cancer therapy 2 . (jcancer.org)
  • The vector of anti-CD22 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD22. (pharmpro.com)
  • The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD22 antibody linked to CD137 (4-1BB) and CD3-zeta signaling domains. (pharmpro.com)
  • T cells engineered using RNA electroporation represent an alternative with the potential for similar efficacy and greater safety when initially targeting novel antigens. (aacrjournals.org)
  • We performed xenograft studies in NSG mice in which we assessed the efficacy of both permanently modified and transiently modified CAR T cells directed against the neuroblastoma antigen GD2 in both local and disseminated disease models. (aacrjournals.org)
  • This in turn will permit downstream studies of T cell receptor (TCR) isolation, cancer antigen identification and molecular characterization of naturally occurring tumor-reactive T cells in human cancer. (upenn.edu)
  • The desired cells can be recovered using a Treg marker such as CD25, GITR, CTLA4, CD137, latent TGF-beta (LAP), GARP (LRRC32) or CD121a/b. (patents.com)
  • Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 (+) T cell responses. (mayo.edu)
  • In mice, he also demonstrated the effectiveness of combining an immunotherapy that inhibits another checkpoint, LAG-3, with one that activates the co-stimulatory molecule 4-1BB (also known as CD137), which plays a role in augmenting the activity of CD4 + and CD8 + T cells as well as B cells, dendritic cells, natural killer cells, macrophages, and other components of the immune system. (cancerresearch.org)
  • It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. (creative-biolabs.com)
  • On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity. (creative-biolabs.com)
  • In neoadjuvant cetuximab-treated patients with head and neck cancer, upregulation of CD137 by intratumoral, cetuximab-activated NK cells correlated with FcgammaRIIIa V/F polymorphism and predicted clinical response. (cusabio.com)
  • Interestingly, for cancer immunotherapy, CD137 becomes expressed on primed T and natural killer (NK) cells, which on ligation provides powerful costimulatory signals. (cun.es)
  • Perturbation of CD137 by CD137L or agonist monoclonal antibodies on activated CD8 T cells protects such antigen-specific cytotoxic T lymphocytes from apoptosis, enhances effector functionalities and favours persistence and memory differentiation. (cun.es)
  • The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro . (springer.com)
  • Chimeric antigen receptor T cells for sustained remissions in leukemia. (springer.com)
  • The CD antigens are protocol used for the identification and investigation of cell surface molecules providing targets for immunophenotyping of cells. (sinobiological.com)
  • To address this issue, we created a series of CARs that contain the T cell receptor-zeta (TCR-zeta) signal transduction domain with the CD28 and/or CD137 (4-1BB) intracellular domains in tandem. (nih.gov)
  • Lentiviral vectors were used to express a single-chain variable fragment that binds mesothelin and that is fused to signaling domains derived from T-cell receptor zeta, CD28, and CD137 (4-1BB). (pnas.org)
  • CD28, CD137) on second and two costimulatory molecules on third-generation CARs. (urotoday.com)
  • Results: ELISA and flow cytometry analysis demonstrated that both HER2 x CD137 and EphA2 x CD137 DART molecules bind their respective target antigens. (aacrjournals.org)
  • Hematological malignancies tend to be more homogenous with a uniform expression of target antigens which may explain the high response rates and durability after CAR-T cell therapy. (urotoday.com)
  • Methods: DART molecules were constructed containing anti-CD137 variable regions together with either anti-HER2 or anti-EphA2 variable regions. (aacrjournals.org)
  • The Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. (clinicaltrials.gov)
  • I. To assess the pharmacodynamic effects of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS- 663513), and/or anti-PD-1 antibody (BMS-936558) on biomarkers in peripheral blood, including the T cell compartments, and serum proteins (cytokines and other immune modulators). (clinicaltrials.gov)
  • To further characterize the occupancy and immune cell function at multiple dose levels of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS-663513), and/or anti-PD-1 antibody (BMS-936558). (clinicaltrials.gov)
  • PART A: This is a dose-escalation study of the monotherapy of Anti-LAG-3 monoclonal antibody BMS-986016 and Anti-CD137 (urelumab). (clinicaltrials.gov)
  • ARM II: Patients receive anti-CD137 (urelumab) IV on day 1. (clinicaltrials.gov)
  • PART B: This is the dose-escalation combination therapy portion study of Anti-LAG-3 monoclonal antibody BMS-986016 plus Anti-PD-1(nivolumab) and Anti-CD137 (urelumab) plus Anti-PD-1 (nivolumab). (clinicaltrials.gov)
  • Moreover, administration of systemic sFLT3L and local poly-ICLC enhanced DC-mediated cross-priming and synergized with anti-CD137- and anti-PD-1-mediated immunostimulation in tumor therapy against B16-ovalbumin-derived melanomas, whereas this function was lost in Batf3 −/− mice. (aacrjournals.org)
  • We show that cross-priming of tumor antigens by BATF3-dependent DCs is a key limiting factor that can be exploited to enhance the antitumor efficacy of anti-PD-1 and anti-CD137 immunostimulatory mAbs. (aacrjournals.org)
  • Programmed death ligand 2 (anti-PD-L2), anti-CD137, anti-CD40, anti-OX40 antibodies. (knowcancer.com)
  • Immunotherapy with agonistic anti-CD137: two sides of a coin. (biomedsearch.com)
  • 4-1BBL antigen is a type 2 transmembrane glycoprotein which is part of the TNF superfamily that is expressed on activated T Lymphocytes. (prospecbio.com)
  • CD137 (ILA/4-1BB) is a member of the tumor necrosis factor receptor family, expressed on activated T lymphocytes. (biovendor.com)
  • While cross-linking of CD137 activates T lymphocytes, cross-linking of the CD137 ligand has the opposite effect. (biovendor.com)
  • This reverse signalling through the CD137 ligand inhibits proliferation of T lymphocytes and induces programmed cell death. (biovendor.com)
  • The expression of CD137 isoforms in lymphocytes has been shown and association of sCD137 with activation-induced cell death demonstrated. (biovendor.com)
  • Here, we evaluated the immunobiology of CD137 in human cancer and the utility of a CD137-positive separation methodology for the identification and enrichment of fresh tumor-reactive tumor-infiltrating lymphocytes (TIL) or tumor-associated lymphocytes (TAL) from ascites for use in adoptive immunotherapy. (aacrjournals.org)
  • The cytometric enumeration and characterization of antigen-specific lymphocytes, as introduced about 15 years ago, has contributed significantly to our understanding of adaptive immune responses in health and disease. (nih.gov)
  • Int.J.Cancer 7,1,1971), and showed that these reactions can be inhibited by tumor antigen and antigen-antibody complexes (PNAS 68,1372,1971) by a mechanism that involves suppressive T lymphocytes (Adv. Immunol. (washington.edu)
  • CD137, also designated ILA and 4-1BB in mouse, belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. (acris-antibodies.com)
  • Crosslinking of the CD137 ligand induces apoptosis in resting lymphocytes. (acris-antibodies.com)
  • CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. (creative-biolabs.com)
  • Cetuximab-mediated NK-cell expression of CD137 on tumor-infiltrating lymphocytes is dependent on FcgammaRIIIa polymorphism. (cusabio.com)
  • We reported previously that established tumors in mice receiving an agonistic mAb to the T cell costimulatory molecule 4-1BB (CD137) regress due to enhanced tumor antigen-specific cytotoxic T lymphocyte responses. (jci.org)
  • We provide evidence that immunological ignorance, rather than anergy or deletion, of tumor antigen-specific CTLs during the progressive growth of tumors prevents costimulation by anti-4-1BB mAb. (jci.org)
  • Breaking CTL ignorance by immunization with a tumor antigen-derived peptide, although insufficient to stimulate a curative CTL response, is necessary for anti-4-1BB mAb to induce a CTL response leading to the regression of established tumors. (jci.org)
  • CD137 increases immune activity to remove tumors in mice. (prospecbio.com)
  • Co-stimulation through CD137 enhances T lymphocyte activation and may enable rejection of tumors in vivo. (biovendor.com)
  • Recently, chimeric antigen receptor (CAR) T cell therapy has shown promising results in hematological tumors and current research is going on in various solid tumors like ovarian cancer. (springer.com)
  • The registered numbers of clinical trials increase annually, and a range of tumor antigens, including CEA, mesothelin, HER2, and GD2, are being targeted for various solid tumors. (hindawi.com)
  • Although current global CD antigen based cancer therapeutic market is dominated for treating hematological malignancies but strong clinical pipeline having over 100 CD antigen directing cancer drugs consists of various drugs which will be used for treating solid tumors like breast cancer, lung cancer, colorectal cancer, prostate cancer etc. (kuickresearch.com)
  • an exponential growth can be experienced by Global CD Antigen Cancer Therapy Market after the approval of anti-CD antigenic cancer drugs for treating solid tumors. (kuickresearch.com)
  • Tumor necrosis factor receptor superfamily member 9, 4-1BB ligand receptor, T-cell antigen 4-1BB, CD137. (prospecbio.com)
  • The collaboration comes more than a year after Gilead completed its $11.9 billion acquisition of Kite Pharma and its chimeric antigen receptor T-cell (CAR-T) pipeline-and nearly two months after Gilead launched a potentially more-than-$1.7 billion partnership with Tango Therapeutics to develop targeted immuno-oncology treatments aimed at up to five targets emerging from Tango's functional genomics-based discovery platform. (genengnews.com)
  • Chimeric antigen receptor T-cell (CAR-T) therapy and T-cell receptor (TCR) therapy. (cancer.net)
  • Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation. (springermedizin.de)
  • Conclusions: HER2 x CD137 and EphA2 x CD137 DART proteins promote T-cell co-stimulation in a tumor antigen-dependent manner and may provide an opportunity to target the CD137 co-stimulatory pathway for cancer immunotherapy, while limiting systemic T-cell activation and related side effects. (aacrjournals.org)
  • Our findings reveal a role for the TNFR-family member CD137 in the immunobiology of human cancer where it is preferentially expressed on tumor-reactive subset of TILs, thus rationalizing its agonistic engagement in vivo and its use in TIL selection for adoptive immunotherapy trials. (aacrjournals.org)
  • Chimeric antigen receptor (CAR) T-cell immunotherapy has revolutionized the treatment of refractory leukemias and lymphomas, but is associated with significant toxicities, namely cytokine release syndrome (CRS) and neurotoxicity. (aacrjournals.org)
  • Combination of radiotherapy with immunotherapy is included as a means of increasing tumor antigen release in metastatic STS. (clinicaltrials.gov)
  • In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. (springer.com)
  • Ensure accurate, reproducible results in immunofluorescence and flow cytometry applications with Thermo Scientific CD137 (4-1BB) Ab-1, Mouse Monoclonal Antibody. (fishersci.com)
  • I. To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM). (clinicaltrials.gov)
  • CARs combine an antigen recognition domain of a specific antibody with an intracellular domain of the CD3-zeta chain or FcγRI protein into a single chimeric protein 1 . (jcancer.org)
  • CD antigens have been used as targets in a wide variety of cancer therapeutics including monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific T-cell engager antibodies, radio immunoconjugates and CAR T-cell therapies. (kuickresearch.com)
  • Global CD antigen based cancer therapy market has evolved since the approval of first CD antigen targeting monoclonal antibody. (kuickresearch.com)
  • The present invention provides methods for the production of Y. pestis protein antigens in plants, as well as methods for their use in the treatment and/or prevention of Y. pestis infection. (freepatentsonline.com)
  • 2. The isolated antigen of claim 1, wherein the Yersinia pestis protein comprises an amino acid sequence as set forth in any of the sequences selected from the group consisting of SEQ ID NOs. (freepatentsonline.com)
  • 3. The isolated antigen of claim 1, wherein the Yersinia pestis protein comprises an amino acid sequence comprising at least two sequences selected from the group consisting of any one of SEQ ID NOs. (freepatentsonline.com)
  • 4. The isolated antigen of claim 3, wherein the Yersinia pestis protein comprises full-length F1 protein and full-length LcrV protein. (freepatentsonline.com)
  • 5. The isolated antigen of claim 3, wherein the Yersinia pestis protein comprises a plurality of variants of F1 protein. (freepatentsonline.com)
  • 7. The isolated antigen of claim 1, wherein the thermostable protein comprises a modified lichenase protein. (freepatentsonline.com)
  • 8. The isolated antigen of claim 7, wherein the coding sequence for lichenase has been optimized for protein expression in plants. (freepatentsonline.com)
  • 9. The isolated antigen of claim 7, wherein the lichenase protein comprises the N-terminal domain, the C-terminal domain, and the surface loop domain of lichenase LicB. (freepatentsonline.com)
  • 10. The isolated antigen of claim 1, wherein the Yersinia pestis protein fused to lichenase is one or more of an N-terminal fusion, a C-terminal fusion, or a surface loop insertion fusion protein. (freepatentsonline.com)
  • Thus, upon CD137 activation by binding of CD137L trimers or by crosslinking with agonist monoclonal antibodies, TRAF1, TRAF2, and TRAF3 are readily recruited to the cytoplasmic domain of CD137, likely as homo- and/or heterotrimers with different configurations, initiating the construction of the CD137 signalosome. (frontiersin.org)
  • The proposed studies on samples from patients with infertility or ovarian cancer for several antigens that are expressed in normal and neoplastic ovary, as well as the corresponding antibodies are likely to improve early diagnosis as well as insight to improve therapy and the chicken model provides a unique opportunity to test hypotheses relating to the role of antigens, antibodies and inflammation in the etiology and progression of ovarian cancer. (washington.edu)
  • and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. (watchlistnews.com)
  • CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. (kuickresearch.com)
  • CD antigens are the basis on which monoclonal antibodies were discovered. (kuickresearch.com)
  • We uncovered a previously unrecognized, antigen-independent effect of CARs expressing the CD137 cytoplasmic domain that likely contributes to the enhanced antileukemic efficacy and survival in tumor bearing mice. (nih.gov)
  • Despite the development of several technologies, allowing to directly or indirectly analyze many aspects of lymphocyte specificity and function, several unresolved issues remain, due to the low frequency of certain antigen-specific lymphocyte subsets and the complexity of T cell antigen recognition. (nih.gov)
  • Analysis of MR1T cell clones revealed specificity for distinct cell-derived antigens and alternative transcriptional strategies for metabolic programming, cell cycle control and functional polarization following antigen stimulation. (elifesciences.org)
  • Among them, the CD137:CD137L pathway is known to modulate innate and adaptive human responses against Mycobacterium tuberculosis. (doaj.org)
  • To overcome these issues, we engineered proteins simultaneously targeting 4-1BB and a tumor stroma or tumor antigen: FAP-4-1BBL (RG7826) and CD19-4-1BBL. (rcsb.org)
  • Our group has tested a CAR directed against CD19 linked to the CD137 (4-1BB) co-stimulatory molecule signaling domain to enhance activation and signaling after recognition of CD19. (jcancer.org)
  • But with continuous efforts in research more CD antigens were found to play significant roles in cancer progression which were then used as cancer therapeutic targets including CD19, CD22, CD38, CD33 and CD3. (kuickresearch.com)
  • In the presence of the relevant antigen-positive cell line, each respective DART molecule was able to promote T-cell proliferation and cytokine release in a HER2 or EphA2-dependent manner. (aacrjournals.org)
  • In contrast, CD137 regulates peripheral monocyte survival by inducing a cytokine release profile, and is mediated by M-CSF and to a lesser extent by granulocyte-macrophage colony-stimulating factor and IL-3. (acris-antibodies.com)
  • Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. (mayo.edu)
  • The CAR itself is a chimeric recombinant molecule that encompasses an extracellular antigen identification zone for Signal 1, a spacer, a transmembrane zone, and intracellular signaling moieties that facilitate Signal 2 costimulation and resultant signal transduction. (urotoday.com)
  • First-generation CARs depended heavily upon a single-chain fragment variable to recognize tumor-associated antigens specifically, however, they lacked the costimulatory intracellular molecule (e.g. (urotoday.com)
  • The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. (creative-biolabs.com)
  • The soluble isoforms of CD137, sCD137, are generated by differential splicing and can be detected at enhanced concentrations in sera of patients suffering from various diseases. (biovendor.com)
  • 4 In our previous studies, we found that the expression of both soluble and membrane‐bound CD137 was significantly elevated in patients with acute coronary syndromes, suggesting that the increased CD137 expression may contribute to the instability of atherosclerotic lesions. (ahajournals.org)
  • Soluble forms of CD137 are found in sera from patients with rheumatoid arthritis and may provide a negative control mechanism for immune responses. (acris-antibodies.com)
  • The gene for human CD137 resides on chromosome 1q36, in a cluster of related genes, and this chromosomal region is associated with mutations in several malignancies. (biovendor.com)
  • https://maria.stanford.edu/ ), a multimodal recurrent neural network for predicting the likelihood of antigen presentation from a gene of interest in the context of specific HLA class II alleles. (nature.com)
  • Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are attractive targets for TCR gene therapy of cancer. (springer.com)
  • Approval of CD antigen directed CAR-T cell therapy has further encouraged public and private sectors to increase investments in research studies related to genomics and technological advancements for feasible gene sequencing and selection of target gene expressing CD antigens. (kuickresearch.com)
  • 3 SNPs (rs161827, rs161818, and rs161810) of the CD137 gene and their association with ischemic stroke were studied in a northern Chinese Han population. (cusabio.com)
  • TRAF adaptor proteins bind to CD137 and transduce the signals which results to the activation of NF-kappaB. (prospecbio.com)
  • To develop a therapeutic modality that reduces the potential for systemic CD137 effects, we applied the DART® bispecific platform to generate proteins that can induce tumor-antigen dependent T-cell activation. (aacrjournals.org)
  • Hence, akin to other members of the TNFR family, it relies on the TNFR-Associated-Factor (TRAF) family of adaptor proteins to build the CD137 signalosome for transducing signals into the cell. (frontiersin.org)
  • In addition, available studies have identified a large number of proteins that are recruited to CD137:TRAF complexes including ubiquitin ligases and proteases, kinases, and modulatory proteins. (frontiersin.org)
  • Current evidence allows to envision the molecular events that might take place in the early stages of CD137-signalosome formation, underscoring the key roles of TRAFs and of K63 and K48-ubiquitination of target proteins in the signaling process. (frontiersin.org)
  • In this study, we show that the Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8 + TIL. (rupress.org)
  • Co-culturing of a CD137/NF-κB reporter cell line with tumor lines expressing HER2 or EphA2 revealed tumor antigen-dependent CD137 pathway activation by HER2 x CD137 and EphA2 x CD137 DART molecules, respectively. (aacrjournals.org)
  • To evaluate the effects of HER2 x CD137 and EphA2 x CD137 DART molecules on T-cell responses, co-stimulation T-cell assays were performed. (aacrjournals.org)
  • Furthermore, the level of tumor antigen-dependent co-stimulation supported by the DART molecules correlated with the level of tumor target expression. (aacrjournals.org)
  • Accurate prediction of antigen presentation by human leukocyte antigen (HLA) class II molecules would be valuable for vaccine development and cancer immunotherapies. (nature.com)
  • The formation of TRAF2-RING dimers between TRAF2 molecules from contiguous trimers would help to establish a multimeric structure of TRAF-trimers that is probably essential for CD137 signaling. (frontiersin.org)
  • Four stimulatory checkpoint molecules are members of the tumor necrosis factor (TNF) receptor superfamily-CD27, CD40, OX40, GITR and CD137. (wikipedia.org)
  • Combination of FAP-4-1BBL with tumor antigen-targeted T cell bispecific (TCB) molecules in human tumor samples led to increased IFN-γ and granzyme B secretion. (rcsb.org)
  • Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) pipeline Target constitutes close to 5 molecules. (researchandmarkets.com)
  • The costimulatory molecule CD137 belongs to the TNFR superfamily ( 1 ). (jimmunol.org)
  • 4-1BB (CD137), a member of the TNF receptor superfamily, is an activation-induced T-cell costimulatory molecule. (aacrjournals.org)
  • Batf3 −/− mice failed to prime an endogenous CTL-mediated immune response toward tumor-associated antigens, including neoantigens. (aacrjournals.org)
  • CD137 are involved in the regulation of a wide range of immune activities. (researchandmarkets.com)
  • In the presence of a T cell receptor signal, they provide potent T cell costimulation strictly dependent on tumor antigen-mediated hyperclustering without systemic activation by FcγR binding. (rcsb.org)
  • It transmits an activation signal to the T cell after antigen is bound. (creative-biolabs.com)
  • Antigen-Driven T-Cell Selection in Patients with Cervical Cancer as Evidenced by T-Cell Receptor Analysis and Recognition of Autologous Tumor. (freepatentsonline.com)
  • Our group also made some of the first MAbs to human cancer antigens (PNAS 76,2927,1978) and demonstrated their utility for targeting anti-cancer agents (Science 261,212,1993). (washington.edu)
  • Therefore, in the 1990s and 2000s, nonmutated tumor antigens shared by patients were favored for cancer vaccine development, yet outcomes were disappointing. (sciencemag.org)
  • "CD Antigen Cancer Therapy Market Outlook and Clinical Trials Insight 2023" report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. (kuickresearch.com)
  • CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. (kuickresearch.com)
  • The current scenario clearly indicates that CD Antigens have acquired a major share in the modern cancer therapy market. (kuickresearch.com)
  • Current market is fledged with a variety of CD antigen targeting cancer therapies. (kuickresearch.com)
  • The market has successfully produced unique CD antigen based cancer therapies. (kuickresearch.com)
  • The future CD antigen based cancer therapy market is going to be highly competitive as the pharmaceutical companies have to ensure that they are producing unique and more advanced products. (kuickresearch.com)
  • Furthermore, CD antigens based cancer therapies has the potential to become popular amongst the patients and physicians as they provide better survival and have justified their high prices in case of some therapies by providing better clinical results than other conventional cancer therapies. (kuickresearch.com)
  • Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. (springer.com)
  • CD137 increases T cell production, IL-2 discharge, survival and cytolytic activity. (prospecbio.com)
  • Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. (wikipedia.org)
  • New formats of CD137 agonist moieties are being clinically developed, seeking potent costimulation targeted to the tumour microenvironment to avoid liver inflammation side effects, that have thus far limited and delayed clinical development. (cun.es)
  • CD137: When this molecule, also called 4-1BB, is bound by CD137 ligand, the result is T-cell proliferation. (wikipedia.org)
  • CD137 pos TILs were sorted and evaluated for antitumor activity in vitro and in vivo . (aacrjournals.org)
  • In addition to in vitro binding measurements, MARIA is trained on peptide HLA ligand sequences identified by mass spectrometry, expression levels of antigen genes and protease cleavage signatures. (nature.com)
  • Bayesian approach to model CD137 signaling in human M. tuberculosis in vitro responses. (doaj.org)
  • In this work, we developed a Bayesian Computational Model (BCM) of in vitro CD137 signaling, devised to fit previously gathered experimental data. (doaj.org)
  • Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. (nature.com)
  • Parallel CD137-based CD4+T cell research showed discrete oligospecific recognition of HSV-1 antigens. (eur.nl)
  • The antigen-specific scFv allows for MHC-independent tumor antigen recognition that initiates robust T-cell stimulation, even in response to previously immunoevasive malignancies ( 7 ). (aacrjournals.org)
  • CD137 (4-1BB, Tnsfr9) is a member of the TNF-receptor (TNFR) superfamily without known intrinsic enzymatic activity in its cytoplasmic domain. (frontiersin.org)
  • It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics development with respective active and dormant or discontinued projects. (researchandmarkets.com)
  • 23. The TCR of claim 16, wherein the TCR recognizes a specific antigen. (google.com.au)
  • Here, we generate a bispecific 4-1BB-agonistic trimerbody targeting the carcinoembryonic antigen (CEA) that is highly expressed in cancers of diverse origins. (frontiersin.org)
  • however, current CD137 agonistic interventions are associated with systemic safety concerns. (aacrjournals.org)
  • An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzyme-digested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2. (aacrjournals.org)